Stay tuned for more details, coming soon.
Michael Sen (born in 1968 in Korschenbroich, Germany) has been Chairman of the Management Board (equivalent to President and CEO) of the DAX 40 company Fresenius since October 1, 2022. He is also Chairman of the Supervisory Board of the listed dialysis provider Fresenius Medical Care. As an international top manager with long-term expertise in various industries with a focus on healthcare and energy, he has many years of experience in successful corporate transformation and realignment.
Fresenius SE (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, the healthcare group with more than 175,000 employees generated €21.5 billion in annual revenue. With its focus on therapy, Fresenius offers products and services for the care of critically and chronically ill patients. Every year, it affects globally the lives of more than 450 million people with its medical products and services.
Michael Sen first joined Fresenius in April 2021 as Chief Executive Officer of Fresenius Kabi. Previously, he was a member of the Management Board at Siemens AG, responsible for the healthcare and energy business. He took Siemens Healthineers public during this time. Prior to this, he served as Chief Financial Officer at the energy group E.ON SE.
Michael Sen is an advocate of “health equity”, with fair access to medical care for all. The business graduate is, among others, a member of the Advisory Council of the German Cancer Research Centre, the Board of Trustees of the American Academy and the Executive Board of Deutsches Aktieninstitut.
